Liquid Biopsy Market Insights :
Liquid Biopsy Market is projected to be worth USD 24.14 Billion by 2030, registering a CAGR of 13.7% during the forecast period (2022-2030), the market was valued at USD 7.60 Billion in 2021. The Multi-gene-parallel Analysis using NGS technology is probable to gain a high revenue share in the forecast period. The sample type segment is categorized into blood sample-based and others. Blood sample-based tests led to the growth of the market with 67.2% of revenue share. In 2021, North America contributed the largest revenue share of 57.2% due to high investment and the existence of several biotechnology firms.
Liquid Biopsy Market Dynamics:
A liquid biopsy is a non-invasive test substitute for invasive biopsies which helps physician to identify tumors and information related to the tumor via a simple blood sample. Moreover, it also helps to identify a particular treatment befitting to the patient.
Driver:
The rising prevalence of cancer combined with the demand for minimally invasive and fast recovery treatments globally is fueling the growth of the liquid biopsy market. Further, increasing investment by individuals in early diagnosis and routine health examination are the factors supporting the growth of the market.
Restraint:
The lower sensitivity of certain liquid biopsies is expected to restrain the growth of the liquid biopsy market. For instance, in some cases false negative test also refers to the relapse of a tumor is not spotted at an early stage of diagnosis.
Opportunity:
The growing importance of companion diagnostics to assist healthcare providers in making a treatment decision for patients based on the best response to the therapy is anticipated to create lucrative opportunities for the liquid biopsy market.
COVID-19 Analysis of Liquid Biopsy Market:
The liquid biopsy market has been significantly impacted due to the covid-19 pandemic in many different parts of the world. Shipments were impacted during the initial lockdown due to a labor shortage and the closure of a manufacturing facility. The pandemic’s initial effects in China were tremendous. However, the nation’s circumstances have stabilized, and all product and service production rates have increased. As a result, it is determined that covid-19’s overall impact on the liquid biopsy market is moderate. Post covid-19 there was a positive impact on the liquid biopsy market as consumers were more focused on health, which increased the demand for the liquid biopsy market.
liquid biopsy Report Coverage:
| Report Attributes | Report Details |
| Study Timeline | 2016-2030 |
| Market Size in 2030 (USD Billion) | 24.14 |
| CAGR (2022-2030) | 13.7% |
| By Technology | Multi-gene-parallel Analysis using NGS, Single Gene Analysis using PCR Microarrays) |
| By Sample Type | Blood Sample-based, Others |
| By Biomarker | Circulating Nucleic Acids, CTC, Exosomes/Microvesicles, Circulating Proteins |
| By geography | North America– (U.S., Canada, Mexico
Europe- (Germany, France, U.K., Russia, Italy, Spain, BENELUX, Rest of Europe) Asia Pacific- (China, Japan, India, South Korea, Australia, ASEAN, Rest of Asia Pacific) Latin America- (Brazil, Argentina, Chile, Rest of Latin America) Middle East and Africa- (GCC, Turkey, Israel, Rest of MEA) |
| Key Players | QIAGEN; Myriad Genetics, Inc; BIOCEPT, Inc; Guardant Health, Inc; F. Hoffmann-La Roche Ltd; Illumina, Inc; Angle plc; Oncimmune; Thermo Fisher Scientific, Inc.; Lucence health Inc.; Freenome holdings, Inc.; Epigenomics AG |
Liquid Biopsy Market Segment Analysis:
By Technology
The market is divided by technology type into Single Gene Analysis using PCR Microarrays, and Multi-gene-parallel Analysis using NGS. The Multi-gene-parallel Analysis using NGS technology is probable to gain a high revenue share in the forecast period. The NGS technology is used to identify various mutations accountable for tumorigenesis. Moreover, this technology also helps to detect resistance structures created from active clones post-treatment. Additionally, swift improvements in NGS technology have led to considerable cost reduction in sequencing with high accuracy. The NGS technology is employed to target panels for highly sensitive and specific ctDNA mutation recognition to enable the diagnosis of unidentified variants. For instance, NGS technology is used to identify patients with MAF of around 0.1% at 59% of stage 1 or 2 lung cancer. Hence, growing advancement in treatment is projected to boost the growth of the market.
By Sample Type
The sample type segment is categorized into blood sample-based and others. Blood sample-based tests led to the growth of the market with 67.2% of revenue share during the forecast period. A blood sample-based test is a type of non-invasive test method with no risk. Further, this test is used to identify or detect microvesicles, CTCs, exosomes, and ctDNAs, which is expected to increase the adoption of blood-based liquid biopsy. To understand tumorigenesis and metastasis circulating biomarkers in blood play a crucial role and help in determining the tumor dynamics during the treatment or progression of the disease. In addition, increasing research activity on blood-based tests for cancer treatment is expected to drive the liquid biopsy market.
By Biomarker
The biomarkers segment is divided into CTC, exosomes/microvesicles, circulating nucleic acids, and circulating proteins. Circulating Nucleic Acids reported the highest revenue share of 38.3% in 2021. The rising application of circulating tumor DNA (ctDNA) in liquid biopsy of cancer is acting as a major driver in the market. Further, ctDNA-based liquid biopsy examination is creating profitable opportunities in monitoring and molecular diagnosis of cancer. Also, ctDNA-based liquid biopsy is proficient in precisely determining tumor development, and prognosis, and assisting in targeted therapy. To identify ctDNA from tumors translational cancer investigators are using liquid biopsies. As detection of ctDNA aids potential biomarkers and supports liquid biopsy applications for cancer detection.
By Region
The liquid biopsy market is divided into four regions such as North America, Europe, Asia-Pacific, and Latin America. In 2021, North America contributed the largest revenue share of 57.2%. The regional growth is driven by the US due to high investment and the existence of several biotechnology firms combined with the development of the test. Further, various organizations in the region such as the American Society of Clinical Oncology (ASCO) assist in the execution of liquid biopsies. This in turn boosted the growth of the liquid biopsy market. Canada followed the US in the implementation of liquid biopsy tests, as FDA-approved tests are standard in these countries. In addition, increase competition, investments by the government in the market are expected to drive the growth of the market.
Liquid Biopsy Market Competitive Landscape:
The competitive landscape of the market has been analyzed in the report, along with the detailed profiles of the major players operating in the industry. Further, the surge in Research and Development (R&D), product innovation, various business strategies, and product launches have accelerated the growth of the liquid biopsy market. Key players in the market include-
- QIAGEN
- BIOCEPT, Inc.
- Guardant Health, Inc.
- Hoffmann-La Roche Ltd.
- Illumina, Inc.
- Angle plc
- Oncimmune
- Thermo Fisher Scientific, Inc.
- Lucence health Inc.
- FreenomeHoldings, Inc.
- EPIGENOMICS AG
- Myriad Genetics, Inc.
Table of Content
-
- Introduction
- Market Introduction
- Market Research Methodology
- Research Process
- Primary Research
- Secondary Research
- Data Collection Technique
- Data Sources
- Market Estimation Methodology
- Limitations of the Study
- Product Picture of Liquid Biopsy
- Global Liquid Biopsy Market: Classification
- Geographic Scope
- Years Considered for the Study
- Research Methodology in brief
- Parent Market Overview
- Overall Liquid Biopsy Market Regional Demand
- Research Programs/Design
- Market Breakdown and Data Triangulation Approach
- Data Source
- Secondary Sources
- Primary Sources
- Primary Interviews
- Average primary breakdown ratio
- Market Dynamics
- Drivers
- Drivers
- Restraints
- Restraints
- Opportunity
- Impact forces on market dynamics
- Impact forces during the forecast years
- Industry Value Chain
- Upstream analysis
- Downstream analysis
- Distribution Channel
- Direct Channel
- Indirect Channel
- Potential Customers
- Manufacturing/Operational Cost Analysis
- Pricing Analysis by Region
- Key Technology Landscape
- Regulatory Analysis
- Porter’s Analysis
- Supplier Power
- Buyer Power
- Substitution Threat
- Threat from New Entry
- Competitive Rivalry
- PESTEL Analysis
- Political Factors
- Economic Factor
- Social Factors
- Technological Factor
- Environmental Factors
- Legal Factor
- Covid-19 impact on Global Economy
- Covid-19 impact on Liquid Biopsydemand
- Post-Covid Impact on Liquid Biopsy MarketDemand
- Impact Analysis of Russia-Ukraine Conflict
- Drivers
- Global Liquid Biopsy MarketSegmentation, by Revenue (USD Billion), (2022-2030)
- By Technology
- Multi-gene-parallel Analysis (NGS)
- Single Gene Analysis (PCR Microarrays)
- By Sample Type
- Blood Sample-based
- Others
- By Biomarkers
- Circulating Nucleic Acids
- CTC
- Exosomes/Microvesicles
- Circulating Proteins
- By Technology
- Global Liquid Biopsy MarketOverview, By Region
- North America Liquid Biopsy MarketRevenue (USD Billion), by Countries, (2022-2030)
- US
- By Technology
- By Sample Type
- By Biomarkers
- Canada
- Mexico
- US
- Europe Liquid Biopsy MarketRevenue (USD Billion), by Countries, (2022-2030)
- France
- UK
- Spain
- Russia
- Italy
- BENELUX
- Asia Pacific Liquid Biopsy MarketRevenue (USD Billion), by Countries, (2022-2030)
- China
- Japan
- Australia
- South Korea
- India
- ASEAN
- North America Liquid Biopsy MarketRevenue (USD Billion), by Countries, (2022-2030)
- Latin America Liquid Biopsy MarketRevenue (USD Billion), by Countries, (2022-2030)
- Brazil
- Argentina
- Chile
- Middle East and Africa Liquid Biopsy MarketRevenue (USD Billion), by Countries, (2022-2030)
- GCC
- Turkey
- South Africa
- Global Liquid Biopsy MarketRevenue: Competitive Analysis, 2021
- Key strategies by players
- Revenue (USD Billion and %), By manufacturers, 2021
- Player Positioning by Market Players, 2021
- Competitive Analysis
- QIAGEN
- Business Overview
- Business Financials (USD billion)
- Product Category, Type, and Specification
- Main Business/Business Overview
- Geographical Analysis
- Recent Development
- Swot Analysis
- Myriad Genetics, Inc.
- BIOCEPT, Inc.
- Guardant Health, Inc.
- Hoffmann-La Roche Ltd.
- Illumina, Inc.
- Angle plc
- Oncimmune
- Thermo Fisher Scientific, Inc.
- Lucence health Inc.
- FreenomeHoldings, Inc.
- EPIGENOMICS AG
- QIAGEN
- Market Research Findings & Conclusion
Disclaimer
- Introduction
Research Methodology
The Market Research Community offers numerous solutions and its full addition in the research methods to be skilled at each step. We use wide-ranging resources to produce the best outcome for our customers. The achievement of a research development is completely reliant on the research methods implemented by the company. We always faithful to our clients to find opportunities by examining the global market and offering economic insights.Market Research Community are proud of our widespread coverage that encompasses the understanding of numerous major industry domains. Company offers consistency in our research report, we also offers on the part of the analysis of forecast across a range of coverage geographies and coverage. The research teams carry out primary and secondary research to carry out and design the data collection methods.